Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
72
天
Long-Term Outcomes of Focal Irreversible Electroporation for Localized Prostate Cancer: Results of a Prospective Pilot Study With Extended Follow-up
作者
Andrey Morozov; Murad Asali; Igor Matkovskiy; Juan Gomez Rivas; Nirmish Singla; Larisa Tsoy; Evgeniy Fisenko; Leonid Spivak; Konstantin Lokshin; Vadim Rudenko; Denis Chinenov; Eric Barret; Dmitry Enikeev展开收起
作者单位
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Urology Department, Barzilai Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel; Assuta Medical Center, Beer Sheva, Ramat Hyal, Ben Gurion University of the Negev, Beer Sheva, Israel; N.V. Sklifosovsky Institute of Clinical Medicine, Sechenov University, Moscow, Russia; Department of Urology, Hospital Clínico San Carlos, Madrid, Spain; Department of Urology, James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD; Institute of Clinical Morphology and Digital Pathology, Sechenov University, Moscow, Russia; Kent and Canterbury Hospital, East Kent Hospitals University Foundation Trust, Canterbury, United Kingdom; Department of Urology, Institut Mutualiste Montsouris, Paris, France; Department of Urology, Rabin Medical Center, Petah Tikva, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Urology, Medical University of Vienna, Vienna, Austria展开收起
292
天
Time to Partial Nephrectomy Versus Cancer-Specific Mortality in 2 to 4 cm Renal Cell Carcinoma
作者
Maximilian Filzmayer; Michele Nicolazzini; Federico Polverino; Michele Petix; Leonardo Quarta; Filippo Orlandi; Nick J. Lee; Jordan A. Goyal; Nicola Longo; Gennaro Musi; Alberto Briganti; Salvatore Micali; Shahrokh F. Shariat; Marina Kosiba; Clara Humke; Miriam I. Traumann; Fred Saad; Felix K.-H. Chun; Pierre I. Karakiewicz展开收起
作者单位
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Urology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany; Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy; Division of Urology, Department of Oncology, University of Turin, Turin, Italy; Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy; Department of Urology, AOU di Modena, University of Modena and Reggio Emilia, Modena, Italy; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, United States; Department of Urology, University of Texas Southwestern Medical Center, Dallas, United States; Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan展开收起
93
天
Rescue Plerixafor-based Mobilization and Outcomes of Salvage High-dose Chemotherapy in Relapsed/Refractory Germ Cell Tumors: A Large Single-center Experience
作者
Sara Bleve; Maria Concetta Cursano; Cecilia Menna; Caterina Gianni; Giuseppe Schepisi; Valentina Gallà; Chiara Casadei; Serena Mangianti; Stefano Baravelli; Accursio Fabio Augello; Francesco Lanza; Giovanni Rosti; Ismaela Anna Vascotto; Ugo De Giorgi展开收起
作者单位
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy; Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy; Cell Processing Laboratory, The Greater Romagna Area Hub Laboratory Pievesestina, Cesena, Italy; Unit of Immunohematology and Transfusion Medicine, Morgagni Pierantoni Hospital, Forlì, Italy; Hematology Unit, Ravenna Hospital, Ravenna, Italy; Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Experimental Medicine, Vito Fazzi Hospital, University of Salento, Lecce, Italy展开收起
69
天
Dual-Tracer 68Ga-PSMA and 68Ga-DOTATATE PET/CT in Advanced Prostate Cancer: Persistent PSMA Expression Despite Clinically Suspected Treatment-Emergent Neuroendocrine Differentiation
作者
Hiroki Sai; Hidetoshi Kuruma; Atsuya Okada; Yuki Enei; Takafumi Yanagisawa; Chieko Okazaki; Shusuke Akamatsu; Nat Lenzo; Kenta Miki; Takahiro Kimura展开收起
作者单位
Bashamichi Sakura Clinic, Yokohama City, Japan; Department of Urology, Nagoya University Graduate School of Medicine, Nagoya City, Japan; Jinsenkai MI Clinic, Toyonaka City, Japan; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; ICON Cancer Centre Theranostics, Perth, Australia; Theranostics Yokohama, Yokohama City, Japan展开收起
100
天
Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma
作者
Uğur Özberk; Fahriye Tuğba Köş; Perihan Perkin; Öznur Bal; Berkay Yeşilyurt; Mehmet Akif Parlar; Serkan Delen; Bülent Yalçın展开收起
作者单位
Department Of Medical Oncology, Ankara City Hospital, Ankara, Türkiye; Department of Internal Medicine, Ankara City Hospital, Ankara, Türkiye展开收起
79
天
Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study
作者
Melanie Mayer; Nicholas J. Seewald; Ernesto Ulloa-Pérez; Blanca Homet Moreno; Chethan Ramamurthy; Aram Babcock; Haojie Li; Ronac Mamtani展开收起
作者单位
Department of Biostatistics, Epidemiology, & Informatics, University of Pennsylvania, Philadelphia, PA; Merck & Co., Inc., Rahway, NJ; Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA展开收起
FAQ
Clinical Genitourinary Cancer审稿要多久?
截至2026-11-14,CrushSCI 收录了 Clinical Genitourinary Cancer 的 15 篇完整审稿记录。最快一篇从收稿到录用用了 30 天(Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC),2026-06-11 收稿,2026-07-11 录用),最慢一篇用了 292 天;平均 97 天,中位数 76 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
